Anti-GD2 CAR-T therapy (Sinobioway Cell Therapy)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-GD2 CAR-T therapy (Sinobioway Cell Therapy)
Drug Alias NameGD2-targeted CAR-T cells - Sinobioway Cell TherapyGD2-specific Chimeric Antigen Receptor-modified T Cells - Sinobioway Cell TherapyCAR-GD2-modified T cells - Sinobioway Cell Therapy
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityAnti-GD2T lymphocyte replacements
TargetsDisialoganglioside GD2
Therapy Area/IndicationsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Sinobioway Bioengineering Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Sinobioway Bioengineering Group Co Ltd
Inactive CompaniesN/A
Active IndicationsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A